First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect
First-in-human study of the safety, pharmacokinetics, and
Suppressing fatty acid synthase by type I interferon and chemical
Acetyl-CoA metabolism as a therapeutic target for cancer
PDF) First-in-human study of the safety, pharmacokinetics, and
Targeting fatty acid uptake and metabolism in cancer cells: A
Acetyl-CoA metabolism as a therapeutic target for cancer
TVB-2640 (Denifanstat, Fatty Acid Synthase Inhibitor 2, FASN-IN-2
First-in-human study of the safety, pharmacokinetics, and
Frontiers First-In-Human Study to Assess the Safety
First-in-human study of the safety, pharmacokinetics, and
Pharmacokinetic behavior of ALT-801 and semaglutide in C57Bl/6J
Emerging roles of fatty acid metabolism in cancer and their
Emerging roles of fatty acid metabolism in cancer and their
FASN inhibitor TVB-3166 prevents S-acylation of the spike protein